A protein called neurofibromin and a competing pathway could be the ticket to a novel gene therapy for a rare pediatric disorder called neurofibromatosis, which is associated with autism and learning difficulties. The proposed therapy could reverse these symptoms, announced officials from the University of Texas (UT) Southwestern on Monday.

Four generous grants from the U.S. Nuclear Regulatory Commission (NRC) have been bestowed on the Worcester Polytechnic Institute in Worcester, Mass., institute officials announced today.

PET/CT with Ga-68 DOTATATE has been found to change treatment plans in a majority of patients receiving initial evaluation and subsequent staging of neuroendocrine tumors (NETs), according to the results of two referring physician surveys published Dec. 11 in the Journal of Nuclear Medicine.

Reading a 3D thresholded SPECT vs. a conventional 2D SPECT has led to a dramatic improvement in sensitivity for the evaluation of attention deficit hyperactive disorder (ADHD), officials at Amen Clinics announced Dec. 9.

Definiens, the global leader in Tissue Phenomics® for oncology diagnostics, today announced the newest version of its leading image analysis software for quantitative digital pathology, Tissue Studio 4.0. The new release provides greater flexibility, more accurate and consistent results, and the ability to use any chromogen for single and dual stain immunohistochemistry (IHC) quantification.

Obese children tend to have an exceptionally responsive sweet tooth—and it shows up as a visible signal in their brains.

Genetic research from John Hopkins and the University of Alabama Birmingham are providing a road map of inflammation linked to autism thanks to a fleet of tissue samples from 72 autistic and healthy brains. Analyses of these tissues showed microglial cells in perpetual hyperdrive, which translates into neuro-inflammation.

A readily available antibiotic drug therapy that happens to promote the expression of a certain neurotransmitter receptor could one day be a means of combatting frontotemporal dementia (FTD), officials from the University of Alabama Birmingham announced Dec. 3.